Ajg511 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-142704 | 01/11/2014 | 14/11/2014 | Phase III study of AJG511 in patients with active ulcerative colitis | Phase III study of AJG511 in patients with active ulcerative colitis | ulcerative colitis | Intervention name : AJG511 INN of the intervention : budesonide Dosage And administration of the intervention : intrarectal Control intervention name : Placebo Dosage And administration of the control intervention : intrarectal | EA Pharma Co.,Ltd. | NULL | 16 | BOTH | 120 | Phase 3 | NULL | ||
| 2 | JPRN-JapicCTI-132294 | 03/10/2013 | Phase II study of AJG511 in patients with active ulcerative colitis | Phase II study of AJG511 in patients with active ulcerative colitis | Ulcerative colitis | Intervention name : AJG511 INN of the intervention : budesonide Dosage And administration of the intervention : intrarectal | Ajinomoto Pharmaceuticals Co., Ltd. | NULL | 16 | 69 | BOTH | Phase 2 | NULL |